Petros Pharmaceuticals, Inc.
PTPI
$0.0849
-$0.007-7.62%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 51.19% | 74.01% | -56.14% | 107.54% | 67.10% |
| Total Depreciation and Amortization | -10.69% | -12.17% | -12.21% | -9.54% | -44.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -109.98% | -64,282.61% | -782.90% | -7,510.86% | -81.33% |
| Change in Net Operating Assets | 146.03% | -125.05% | 500.41% | 12.58% | -163.11% |
| Cash from Operations | 80.94% | -190.58% | -51.63% | -43.92% | -131.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.58% | -4.57% | -- | -102.16% | -1.82% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -118.97% | -439.18% | -213.42% | -1,182.06% | 4,141.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.68% | -287.12% | -103.97% | -163.93% | 600.86% |
